ProCE Banner Activity

CE / CME

Test Your Skills: Understanding the Current Biomarker Landscape for Patients With Advanced Colorectal Cancer

Case Challenge

In this interactive case challenge, answer questions to make clinical decisions for optimizing individualized treatment for a patient with newly diagnosed advanced CRC. 

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Released: September 13, 2024

Expiration: September 12, 2025

Share

Faculty

Alanna Church

Alanna Church, MD

Associate Director, Laboratory for Molecular Pediatric Pathology (LaMPP)
Program Director, Harvard Molecular Genetic Pathology Fellowship
Assistant Professor, Harvard Medical School
Boston Children’s Hospital
Boston, Massachusetts

James M Cleary

James M Cleary, MD, PhD

Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC, in partnership with Q Synthesis and the Association for Molecular Pathology

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Partners

AMP

ProCE Banner

Q Synthesis LLC

ProCE Banner

Target Audience

Oncologists, pathologists, nurse practitioners, physician associates, pharmacists, and other healthcare professionals who manage patients with cancer within 3 community and academic cancer centers.

Program Learning Goal

The overall initiative aim by the conclusion of this project is to improve clinical outcomes in patients with advanced solid tumors harboring actionable biomarkers among participating clinic sites.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Accurately interpret molecular pathology results to select appropriate targeted therapies for patients with advanced solid tumors prior to initiating therapy

  • Implement an effective, efficient evidence-based process for the timely detection of actionable biomarkers that may affect treatment planning in patients with advanced solid tumors

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Alanna Church, MD

Associate Director, Laboratory for Molecular Pediatric Pathology (LaMPP)
Program Director, Harvard Molecular Genetic Pathology Fellowship
Assistant Professor, Harvard Medical School
Boston Children’s Hospital
Boston, Massachusetts

Alanna Church, MD: consultant/advisor/speaker: Bayer.

James M Cleary, MD, PhD

Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

James M. Cleary, MD, PhD: consultant/advisor/speaker: Blueprint, Incyte; researcher: GlaxoSmithKline (Tesaro), Merck; other material or financial support: Arcus, AstraZeneca, Bayer, Esperas Pharma, Pyxis; data and safety monitoring board: AstraZeneca.

The planners and content peer reviewers from Clinical Care Options, LLC, Q Synthesis, and the Association for Molecular Pathology do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, RNP, AOCNP, as noted below.

Kristi K. Orbaugh, MSN, RNP, AOCNPconsultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Daichii Sankyo, Eli Lilly, Gilead, Pfizer, Regeneron, SOBI.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 13, 2024, through September 12, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO), Q Synthesis, and the Association for Molecular Pathology. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-24-228-H01-P 

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until September 12, 2025. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. 

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS). 

CME for MIPS

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). 

In order to fulfill requirements for MIPS improvement activity, participants will need to fill out 2 brief follow-up surveys at 30- and 90-days post-activity. 

CME Passport

662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.